We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+7.14%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$814M
(+22%)
Cap. Flow
+$233M
Cap. Flow
% of AUM
5.17%
Top 10 Holdings %
Top 10 Hldgs %
40.45%
Holding
134
New
22
Increased
42
Reduced
20
Closed
29
Avg Time Held Equity + Options
0.5
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$94.6M |
| 2 |
AstraZeneca
AZN
|
+$82.2M |
| 3 |
Baxter International
BAX
|
+$68.1M |
| 4 |
Caribou Biosciences
CRBU
|
+$60.5M |
| 5 |
Stevanato
STVN
|
+$59.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maravai LifeSciences
MRVI
|
+$124M |
| 2 |
Medtronic
MDT
|
+$66.4M |
| 3 |
Biogen
BIIB
|
+$63.7M |
| 4 |
NeoGenomics
NEO
|
+$61.7M |
| 5 |
Eli Lilly
LLY
|
+$58.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.27% |
| 2 | Miscellaneous | 13.11% |
| 3 | Technology | 0.99% |
| 4 | Financials | 0.64% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.9B
| $380M | 8.41% |
+3,021,000
| New | +$389M |
2021 Q3
0 quarters
|
|
|
XLRN
2
CALL
DELISTED
Acceleron Pharma
XLRN
| $211M | 4.68% |
+1,228,100
| New | +$161M |
2021 Q3
0 quarters
|
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $188M | 4.16% |
1,062,400
+309,400
| +41% | +$49.8M |
2020 Q3
4 quarters
|
|
4
Arvinas
ARVN
$468M
| $184M | 4.07% |
2,234,700
+380,700
| +21% | +$33.6M |
2020 Q2
5 quarters
|
|
5
AbbVie
ABBV
$501B
| $174M | 3.86% |
1,613,200
+128,800
| +9% | +$14.7M |
2019 Q4
7 quarters
|
|
6
Vertex Pharmaceuticals
VRTX
$129B
| $168M | 3.72% |
926,400
-23,600
| -2% | -$4.61M |
2020 Q4
3 quarters
|
|
7
Zentalis Pharmaceuticals
ZNTL
$212M
| $166M | 3.68% |
2,493,800
+333,800
| +15% | +$19.3M |
2020 Q2
5 quarters
|
|
8
Avantor
AVTR
$10.9B
| $133M | 2.94% |
3,247,700
+67,700
| +2% | +$2.65M |
2020 Q2
5 quarters
|
|
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $130M | 2.88% |
934,200
+51,700
| +6% | +$6.46M |
2020 Q1
6 quarters
|
|
10
Syndax Pharmaceuticals
SNDX
$1.22B
| $92.2M | 2.04% |
4,823,400
+208,400
| +5% | +$3.47M |
2020 Q2
5 quarters
|
|
|
11
Regeneron Pharmaceuticals
REGN
$82B
| $92.2M | 2.04% |
+152,300
| New | +$94.6M |
2021 Q3
0 quarters
|
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $91.2M | 2.02% |
537,000
-103,000
| -16% | -$16M |
2021 Q1
2 quarters
|
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $90.5M | 2% |
826,000
+258,000
| +45% | +$26.8M |
2019 Q4
7 quarters
|
|
14
DELISTED
Blueprint Medicines
BPMC
| $85.5M | 1.9% |
832,000
+268,800
| +48% | +$25M |
2020 Q4
3 quarters
|
|
|
15
AstraZeneca
AZN
$259B
| $84.8M | 1.88% |
+706,000
| New | +$82.2M |
2021 Q3
0 quarters
|
|
16
Neurocrine Biosciences
NBIX
$13.9B
| $81.4M | 1.8% |
848,900
+167,900
| +25% | +$15.9M |
2020 Q4
3 quarters
|
|
17
Alnylam Pharmaceuticals
ALNY
$31.3B
| $80.6M | 1.79% |
427,000
+232,000
| +119% | +$43.5M |
2021 Q1
2 quarters
|
|
|
18
Eli Lilly
LLY
$1.12T
| $76.2M | 1.69% |
330,000
-235,500
| -42% | -$58.1M |
2021 Q2
1 quarter
|
|
19
Nuvation Bio
NUVB
$1.67B
| $72.2M | 1.6% |
7,263,488
+297,112
| +4% | +$2.69M |
2021 Q1
2 quarters
|
|
20
Natera
NTRA
$58.3B
| $71.2M | 1.58% |
638,700
+202,700
| +46% | +$23.2M |
2020 Q3
4 quarters
|
|
21
DELISTED
Hologic
HOLX
| $69.8M | 1.55% |
945,400
-263,400
| -22% | -$19.8M |
2021 Q2
1 quarter
|
|
|
22
Baxter International
BAX
$13.3B
| $69.3M | 1.54% |
+862,000
| New | +$68.1M |
2021 Q3
0 quarters
|
|
|
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $67.8M | 1.5% |
1,139,000
+196,000
| +21% | +$11.6M |
2020 Q4
3 quarters
|
|
|
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $66.6M | 1.48% |
4,100,000
+2,699,990
| +193% | +$29.4M |
2021 Q2
1 quarter
|
|
25
United Therapeutics
UTHR
$23.2B
| $64.8M | 1.44% |
351,000
+114,600
| +48% | +$22.6M |
2021 Q2
1 quarter
|
|
Similar funds
ANB
CWM
RIP
TAM
B
PWS
LWP
TAA
Avidity Partners Management's Q3 2021 Portfolio in Review
As of Q3 2021, Avidity Partners Management held 134 positions worth $4.51B, up 22% from $3.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Avidity Partners Management deployed $233M of net new capital in Q3 2021, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Eli Lilly, an estimated $58.1M trimmed.
- Avidity Partners Management's largest Q3 2021 buy was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
- Avidity Partners Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $49.8M increase.
- Avidity Partners Management's biggest Q3 2021 reduction was Eli Lilly, cutting an estimated $58.1M.
- Avidity Partners Management fully exited Maravai LifeSciences in Q3 2021, selling an estimated $124M.
- Avidity Partners Management's ten largest holdings make up 40% of its $4.51B portfolio in Q3 2021.
- Avidity Partners Management opened 22 new positions and closed 29 in Q3 2021.
- Avidity Partners Management's portfolio value rose 22% quarter-over-quarter to $4.51B.
Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.